EN | RU
EN | RU

Help Support

Back

Continuation vs. discontinuation of renin-angiotensin system inhibitors in hospitalized COVID-19 patients

Continuation vs. discontinuation of renin-angiotensin system inhibitors in hospitalized COVID-19 patients Continuation vs. discontinuation of renin-angiotensin system inhibitors in hospitalized COVID-19 patients
Continuation vs. discontinuation of renin-angiotensin system inhibitors in hospitalized COVID-19 patients Continuation vs. discontinuation of renin-angiotensin system inhibitors in hospitalized COVID-19 patients

An open-label, prospective, randomized trial (REPLACE COVID) was performed to determine if continuing versus discontinuing renin-angiotensin system inhibitors impact outcomes in coronavirus-infected 152 subjects.

See All

Key take away

Renin-angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) can be continued safely in individuals hospitalized with coronavirus disease (COVID)-19  unless there is a definite medical contraindication to the ongoing treatment.

Background

An open-label, prospective, randomized trial (REPLACE COVID) was performed to determine if continuing versus discontinuing renin-angiotensin system inhibitors impact outcomes in coronavirus-infected 152 subjects.

Method

Individuals (age 18 years and older) were hospitalized with COVID-19 and were being given a renin-angiotensin system inhibitor therapy prior to hospitalization. Subjects with contraindications to continuing or discontinuing of renin-angiotensin system inhibitor treatment were not included.

Utilizing a permuted block randomization, subjects were randomized to continuation or discontinuation of their renin-angiotensin system inhibitor  (Group A: Continuation arm [n=75]; Group B: Discontinuation arm [n=77]). Utilizing a secure web-based randomization system, the allocation was concealed.

The major endpoint was a global rank score in which the subjects were ranked across four hierarchical tiers including the duration of mechanical ventilation, time to mortality, time on renal replacement or vasopressor treatment, and multiorgan dysfunction during hospitalization. In intention-to-treat population, primary assessment was carried out.

Result

Compared to Group B, Group A was found to have no effect on the global rank score. Both the groups displayed comparable outcomes. The percentage of individuals: (i) requiring intensive care unit admission or invasive mechanical ventilation, (ii) died (iii) having at least one adverse event is shown in the below table:


During follow-up, no difference in serum potassium, creatinine, or blood pressure was noted between the cohorts.

Conclusion

Continuation in comparison with discontinuation of renin-angiotensin system inhibitor treatment does not considerably impact the severity or duration of hospitalization. 

Source:

The Lancet Respiratory Medicine

Article:

Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

Authors:

Jordana B Cohen et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: